Eledon Pharmaceuticals
ELDN
35 hedge funds and large institutions have $52.1M invested in Eledon Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 10 increasing their positions, 12 reducing their positions, and 4 closing their positions.
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
3% more funds holding
Funds holding: 34 → 35 (+1)
6.91% less ownership
Funds ownership: 65.85% → 58.94% (-6.9%)
17% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 12
30% less capital invested
Capital invested by funds: $74.5M → $52.1M (-$22.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.22M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
+$1.75M |
| 3 |
EP
Eversept Partners
New York
|
+$797K |
| 4 |
Two Sigma Investments
New York
|
+$404K |
| 5 |
Two Sigma Advisers
New York
|
+$263K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$5.18M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$3.1M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.41M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
-$1.93M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$772K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Millennium Management
New York
| $65K | -$52K | -7,444 | -41% |
|
27
Ensign Peak Advisors
Salt Lake City,
Utah
| $45K | -$202K | -28,883 | -80% |
|
28
Rockefeller Capital Management
New York
| $10K | – | – | – |
|
|
SWM
29
Spire Wealth Management
Mclean,
Virginia
| $5K | – | – | – |
|
30
Wells Fargo
San Francisco,
California
| $1K | -$28 | -4 | -4% |
|
31
Bank of America
Charlotte,
North Carolina
| $1K | +$489 | +70 | +50% |
|
|
32
Janus Henderson Group
London,
United Kingdom
| – | -$1.93M | -245,095 | Closed |
|
|
TRCT
33
Tower Research Capital (TRC)
New York
| – | -$5K | -643 | Closed |
|
|
CSS
34
Cubist Systematic Strategies
Stamford,
Connecticut
| – | -$5K | -600 | Closed |
|
35
JP Morgan Chase
New York
| – | -$322 | -46 | -70% |
|
|
JCM
36
Jacobi Capital Management
Pittston,
Pennsylvania
| – | +$21 | +3 | New |
|
ELDN Hedge Fund Activity: Q3 2021 in Review
35 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Eledon Pharmaceuticals (ELDN) for Q3 2021, worth a combined $52.1M — down 30% from $74.5M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new ELDN positions and 4 closed out — a net gain of 1 holder — while 10 added to existing stakes and 12 trimmed.
The largest buyer was Vanguard Group, adding an estimated $3.22M. The largest seller was Morgan Stanley, cutting an estimated $5.18M.
- 35 institutional investors held Eledon Pharmaceuticals (ELDN) as of Q3 2021, up from 34 in Q2 2021.
- Funds reported $52.1M of Eledon Pharmaceuticals stock for Q3 2021, down 30% quarter-over-quarter.
- 5 funds opened new Eledon Pharmaceuticals positions in Q3 2021 and 4 closed out, a net change of +1 holder.
- The largest Eledon Pharmaceuticals buyer in Q3 2021 was Vanguard Group, an estimated $3.22M added.
- The largest Eledon Pharmaceuticals seller in Q3 2021 was Morgan Stanley, an estimated $5.18M sold.
Based on aggregated 13F filings for Q3 2021.